Cell Genesys’ GVAX (correction)
Executive Summary
Cell Genesys estimates the timing of the pre-planned interim analysis from VITAL-1, the first of two ongoing Phase III trials of GVAX immunotherapy for prostate cancer, to be in the first half of 2008. A recent article misstates that the interim analysis of two Phase III trials are scheduled for the second half of 2008 (1"The Pink Sheet" Oct. 29, 2007, p. 30)...